Breast cancer-specific survival in patients with HER2-positive, node-negative T1a and T1b breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Breast cancer-specific survival in patients with HER2-positive, node-negative T1a and T1b breast cancer

Published:2018 Issue: Volume:16 Page:38-44
ISSN:2468-2942
Container-title:Cancer Treatment and Research Communications
language:en
Short-container-title:Cancer Treatment and Research Communications

Author:

Parikh Mamta,Galkin Maria,Brunson Ann^ORCID,Keegan Theresa,Chew Helen K

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. Amplification of a novel v-erbB-related gene in a human mammary carcinoma;King;Science,1985

2. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

3. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas;Press;J. Clin. Oncol.,1997

4. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease;Cobleigh;J. Clin. Oncol.,1999

5. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N. Engl. J. Med.,2001

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic factor analysis and clinical significance of HER‑2‑positive breast cancers with negative lymph nodes and a tumor diameter ≤1 cm;Oncology Letters;2023-09-28

2. Are We Overtreating Patients With T1a HER2+ Breast Cancer? An Analysis of the National Cancer Database;Clinical Breast Cancer;2022-12

3. Single Cell Genetic Profiling of Tumors of Breast Cancer Patients Aged 50 Years and Older Reveals Enormous Intratumor Heterogeneity Independent of Individual Prognosis;Cancers;2021-07-05

4. Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy;npj Breast Cancer;2021-03-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3